CSL Limited - Product Pipeline Review - 2015

Published: Oct, 2015 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CSL Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'CSL Limited - Product Pipeline Review - 2015', provides an overview of the CSL Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CSL Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CSL Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CSL Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CSL Limited's pipeline products

Reasons to Buy

- Evaluate CSL Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CSL Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CSL Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CSL Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CSL Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of CSL Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents
 2
List of Tables 6
List of Figures 6
CSL Limited Snapshot 7
CSL Limited Overview 7
Key Information 7
Key Facts 7
CSL Limited - Research and Development Overview 8
Key Therapeutic Areas 8
CSL Limited - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
CSL Limited - Pipeline Products Glance 18
CSL Limited - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Filing rejected/Withdrawn Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
CSL Limited - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
CSL Limited - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
CSL Limited - Drug Profiles 25
albutrepenonacog alfa 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
antihemophilic factor (recombinant) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
haemophilus influenzae [serotype B] vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
seasonal influenza (quadrivalent) vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(prothrombin + coagulation factor VII human + coagulation factor IX human + coagulation factor X human + protein C + protein S human) 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
C1 esterase inhibitor (human) 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CSL-689 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CSL-112 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CSL-311 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
factor XIII (human) 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
influenza [strain H5N1] vaccine 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
seasonal influenza (trivalent) vaccine 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
influenza [strain A/H3N2] (monovalent) vaccine 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
influenza [strain H7N9] (monovalent) vaccine 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
2H-10 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CSL-312 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CSL-324 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CSL-346 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CSL-650 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drug for Undisclosed Indication 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibody for Hematological Disorders 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibodies for Undisclosed Indication 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PODCRC-OHS 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Proteins for Undisclosed Indication 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Recombinant Protein for Hemophilia 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CSL Limited - Pipeline Analysis 58
CSL Limited - Pipeline Products by Target 58
CSL Limited - Pipeline Products by Route of Administration 59
CSL Limited - Pipeline Products by Molecule Type 60
CSL Limited - Pipeline Products by Mechanism of Action 61
CSL Limited - Recent Pipeline Updates 62
CSL Limited - Dormant Projects 72
CSL Limited - Company Statement 73
CSL Limited - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables

CSL Limited, Key Information 7
CSL Limited, Key Facts 7
CSL Limited - Pipeline by Indication, 2015 9
CSL Limited - Pipeline by Stage of Development, 2015 11
CSL Limited - Monotherapy Products in Pipeline, 2015 12
CSL Limited - Combination Treatment Modalities in Pipeline, 2015 13
CSL Limited - Partnered Products in Pipeline, 2015 14
CSL Limited - Partnered Products/ Combination Treatment Modalities, 2015 15
CSL Limited - Out-Licensed Products in Pipeline, 2015 16
CSL Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015 17
CSL Limited - Pre-Registration, 2015 18
CSL Limited - Filing rejected/Withdrawn, 2015 19
CSL Limited - Phase III, 2015 20
CSL Limited - Phase II, 2015 21
CSL Limited - Phase I, 2015 22
CSL Limited - Preclinical, 2015 23
CSL Limited - Discovery, 2015 24
CSL Limited - Pipeline by Target, 2015 58
CSL Limited - Pipeline by Route of Administration, 2015 59
CSL Limited - Pipeline by Molecule Type, 2015 60
CSL Limited - Pipeline Products by Mechanism of Action, 2015 61
CSL Limited - Recent Pipeline Updates, 2015 62
CSL Limited - Dormant Developmental Projects,2015 72
CSL Limited, Other Locations 74
CSL Limited, Subsidiaries 74